G-Plans

About G-Plans

G-Plans was founded in 2020 and has carved out a distinctive niche in the GLP-1 telehealth landscape by combining brand-name medication prescribing with AI-powered meal planning and optional prepared meal delivery. The platform prescribes Ozempic (semaglutide) and Zepbound (tirzepatide) — both FDA-approved brand-name medications — at monthly costs ranging from $99 to $199 for the platform fee, with medication costs handled separately through insurance or pharmacy pricing. This hybrid model of pharmaceutical access plus nutritional technology aims to address the common criticism that GLP-1 programs neglect the dietary side of weight management.

The AI meal planning system is G-Plans’ signature feature. After completing a metabolic assessment, patients receive personalized meal plans generated by the platform’s algorithm, which accounts for dietary preferences, caloric targets, and macronutrient ratios. For patients who want the convenience factor taken further, G-Plans offers optional meal delivery through partner services. The platform also provides access to a registered dietitian for consultations, and the overall support level is high relative to its price point, with regular check-ins and nutritional guidance built into the program.

However, G-Plans carries an F rating with the Better Business Bureau — the lowest grade available — which is a significant concern that prospective patients must weigh carefully. BBB ratings reflect factors including complaint volume, complaint resolution, and business transparency. An F rating typically indicates a pattern of unresolved consumer complaints or failure to respond to the BBB’s inquiries. Our editorial team strongly recommends that patients research the nature of these complaints before enrolling and document all communications and billing agreements with the platform.

G-Plans does not have a Trustpilot profile, and the platform does not accept insurance for its program fees, though patients may be able to use insurance for the brand-name medications themselves through their pharmacy. The lack of independent consumer review data combined with the F BBB rating creates a transparency gap that is difficult to overlook. The clinical model — brand-name medications, dietitian access, AI meal planning — is genuinely innovative, but the business practices reflected in the BBB rating introduce risk that patients should carefully evaluate.

G-Plans represents an intriguing concept with execution concerns. The combination of brand-name GLP-1 medications, AI-driven nutrition planning, and meal delivery addresses real gaps in the telehealth weight loss market. The dietitian access and high support level add clinical credibility. But the F BBB rating casts a shadow over the patient experience, and the absence of insurance acceptance and independent reviews makes it harder to recommend without reservation. Patients drawn to G-Plans’ unique features should proceed with due diligence, clear billing documentation, and realistic expectations about customer service.

G-Plans GLP-1 Medications

At a Glance